Protection assessments indicated that gastrointestinal adverse situations, principally nausea and diarrhea, have been dose-dependent but normally delicate and transient. These conclusions established the therapeutic window and informed dose collection for subsequent Phase three trials.Continued refinement of formulation and dosing methods may even